Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Suga Tacitly Warns against Watering Down “Annual” Price Revision Plan: CEFP
May 24, 2017
- CEFP Private Members Push Smaller Scope for Price Maintenance Premium, Different Rule for “Me-Too” Meds
May 24, 2017
- Health Minister Pitches Revision to Corporate Eligibility Criteria for Price Maintenance Premium: CEFP
May 24, 2017
- Time Has Arrived to Discuss Formularies at Medical Institutions: MHLW Official
May 23, 2017
- MHLW to Set Deadline to Achieve 80% Generic Goal for “September 2020”
May 23, 2017
- MHLW Council Recognizes Unmet Medical Need for Off-Label Use of 3 Drugs
May 19, 2017
- Maintain Prices for On-Patent Drugs, Off-Year Revisions Should Only Cover Limited Products: FPMAJ
May 19, 2017
- Lawmakers Hear from EFPIA, Say They Didn’t Know Japan Drug Market Would Shrink
May 19, 2017
- Standard Operating Profit Rate for Cost Calculation Pricing Rule Updated to 14.7%: Chuikyo
May 19, 2017
- MHLW Discussing Restrictions on Prescriptions of Codeine-Containing Medicines to Children
May 19, 2017
- JPWA Calls for Off-Year Surveys Covering All Products: Chuikyo Hearing
May 19, 2017
- JGA Calls for Elimination of Price Bracket Grouping Rule for Listed Generics
May 19, 2017
- Global Headquarters Watching Japan, Keep Drug Prices for Patented Period: PhRMA, EFPIA
May 19, 2017
- Social Security Council Subcommittee Negative about Reference Pricing System
May 18, 2017
- FPMAJ, EFPIA See Need to Revisit Cost-Based Pricing Method: Chuikyo
May 18, 2017
- MHLW Advisory Panel to Review Eli Lilly’s JAK Inhibitor Baricitinib on May 30
May 18, 2017
- (Update) 3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing
May 18, 2017
- MHLW Study Group to Issue Report Calling for Guidelines to Promote Efficient Development of Biosimilars
May 18, 2017
- Japan Drug Market Could Shrink Annual 1.5% by FY2026: EFPIA Simulation
May 17, 2017
- Continue Price Maintenance Scheme without Shedding Eligible Products: PhRMA
May 17, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…